

surrounding normal tissues. We retrospectively evaluated the safety and efficacy of high dose proton beam therapy (PBT) in patients with stage I non-small cell lung cancer (NSCLC).

Material and Methods: Between December 1999 and September 2006, 77 patients with stage I NSCLC were treated by PBT in our institution. The indication of PBT were (1) clinical stage I NSCLC, (2) PaO₂ > 60 torr, (3) medically inoperable, or refusal of surgery, (4) performance status 0–2, (5) written informed consent. The target volume was defined as the gross tumor volume plus appropriate margins for subclinical tumor extension, set-up error and respiratory motion. Treatment was performed using respiratory gating. A total dose of 70–94 Gy_E was delivered in 20 fractions over 4 to 5 weeks. Kaplan-Meier method and CTC-AE version 3.0 were used to assess survival and toxicity.

Results: Patients characteristics were as follows: median age 75 years (range, 52 to 87); male/female, 54/23; Stage IA/IB, 43/34; squamous/adenocarcinoma/others, 28/23/26; total dose 70/80/88/94 Gy_E, 3/57/16/1. The initial response rate was 74% (95% confidence interval (CI), 63 to 83%). With a median follow-up period of 24 months (range, 3 to 82 months), the 2-year local progression-free and overall survivals were 94% (95%CI, 87 to 99%) and 91% (95% CI, 83 to 99%), respectively. No severe acute toxicity was observed. Late grade 2 and grade 3 pulmonary toxicities were observed in 5 and 3 patients, respectively. Four patients experienced fractures of ribs within irradiated volume. The 2-year loco-regional progression-free survivals in stage IA and IB patients were 95% (95% CI, 88 to 100%) and 67% (95% CI, 50 to 84%), respectively. Six of 8 patients who suffered late grade 2 or greater pulmonary toxicities had stage IB disease.

Conclusions: Updated results shows that PBT is a promising treatment modality for stage I NSCLC, although loco-regional recurrences and late pulmonary toxicities in stage IB patients were substantial. Further investigation of PBT for stage I NSCLC is warranted.

910

POSTER

MVCT image-guidance for abdominal and retroperitoneal IMRT target volumes

M. Fuss¹, C. Shi², N. Papanikolaou². ¹Oregon Health Sciences University, Department of Radiation Medicine, Portland Oregon, USA; ²Cancer Therapy & Research Center, Medical Physics, San Antonio Texas, USA

Purpose: Mega-voltage CT (MVCT) image-guidance afforded by the TomoTherapy HiArt helical tomotherapy system provides limited soft-tissue contrast and has not been evaluated with regard to its utility in localizing upper abdominal and retroperitoneal soft-tissue radiation target volumes. We analyzed automated system generated patient translational and rotational corrections to match simulation target setup based on mutual information fusion (MI), and evaluated if the MVCT image quality was sufficient to judge the accuracy of MI image-fusion. We assessed how often subsequent user interaction was needed for optimized target setup and compared MI fusion derived positional corrections with user setup corrections.

Results: In 159 MVCT studies of 14 patients with typical upper abdominal and retroperitoneal radiation target volumes, user setup corrections were required for optimized target setup in 84.3%. Mean absolute x, y, z corrections suggested by MI fusion were 3.1, 4.4, and 7.8 mm; mean rotation was 0.5 degrees. Mean respective user setup corrections were 3.7, 5.9, and 9.2 mm, with rotations of 1.0 degree. The mean 3D vector of setup correction was 10.6, and 13.1 mm by MI, and user assessment, respectively. Differences in 3D vector length between automated and user setup exceeded 5, 10, and 15 mm in 25%, 11.2%, and 3.9%, respectively. Automated MI fusion provided on average 76% of the setup correction established by the expert user. MVCT image quality did not allow assessment of MI fusion quality in 7/159 attempts (4.4%). MVCT image quality was judged good, fair and poor in 71 (46.7%), 66 (43.4%), and 15 (9.9%) of the remaining attempts. Operative clips aided in establishing appropriate setup, while gas in stomach and bowel caused detriments in image quality. Targets embedded into soft tissue organs such as liver metastases and hepatobiliary tumors were generally poorly visualized.

Conclusion: Despite the limited soft-tissue contrast, MVCT can be a valid imaging modality for image-guidance of upper abdominal and retroperitoneal soft-tissue radiation target volumes. However, in individual patients and in the absence of fiducials within the target volume, MVCT may fail to provide imaging allowing discerning a soft-tissue target volume. While the system integrated automated image-fusion provides for a seamless clinical workflow, expert user online target location assessment was frequently needed to derive an optimal target setup for tomotherapy delivery.

911

POSTER

Changes in the process of care for small-cell lung cancer (SCLC): Results of the 99-01 Patterns of Care Study (PCS) nationwide survey in Japan

T. Uno¹, M. Sumi², M. Mitsumori³, H. Numasaki⁴, H. Ikeda², T. Teshima⁴. ¹Chiba university Graduate School of Medicine, Radiology, Chiba, Japan; ²National Cancer Center, Radiation Oncology, Tokyo, Japan; ³Kyoto University Graduate School of Medicine, Therapeutic Radiology and Oncology, Kyoto, Japan; ⁴Osaka University Graduate School of Medicine, Medical Physics and Engineering, Osaka, Japan

Background: This study was undertaken to evaluate evidence-based changes in the care process for small-cell lung cancer (SCLC) in Japan through the Patterns of Care Study (PCS) nationwide survey.

Materials and Methods: From July 2002, the PCS conducted a second nationwide survey of care process for stage I-III SCLC patients treated with thoracic radiotherapy (TRT) between 1999–2001. PCS investigated; (1) patient background, (2) work-up studies, (3) process of TRT, and (4) process of chemotherapy. Practice patterns of 99–01 PCS were compared with those of 95–97 PCS.

Results: By using two-stage cluster sampling, the PCS collected data for 139 eligible SCLC patients (men to women ratio, 5:1; median age, 69; age >70, 43%; KPS >70, 73%; stage III, 89%). Pre-treatment work-up study included chest CT in 96%, fiberoptic scope in 93%, brain CT or MRI in 86%, bone scintigraphy in 79%. The median total dose of TRT was 5000 cGy. Twice-daily radiotherapy (BID) was used in 43%. The median field size of TRT was 12 × 14 cm, including ipsilateral hilus in 96%, ipsilateral mediastinum in 96%, contralateral mediastinum in 84%, and contralateral hilus in 17%. Field reduction during TRT course in 61%. The most predominantly used photon energy was 10 MV (77%), whereas obsolete technique using Co-60 or X-ray energy <6 MV comprised 12%. 3D-conformal therapy was used in 12%. Dose prescription was at an isodose line in 15%. CT-simulation was performed in 40%. Only 12 patients (9%) received prophylactic cranial irradiation (PCI). Ninety-two percent received systemic chemotherapy, of those, platinum based chemotherapy constituted 98%, and 73% were treated by concurrent chemoradiation (CCRT). Treatment by IRB-approved protocol was only 6 cases (4%). Compared with the previous 95–97 PCS, significant increases in the use of CCRT (37% to 73%, P < 0.0001 by Chi-square test), BID-TRT (19% to 43%, P < 0.0001), and PCI (2% to 9%, P = 0.01) in the management of SCLC could be detected, although the absolute number of patients receiving PCI was still extremely low.

Conclusions: Evidence-based CCRT and BID-TRT had well penetrated into clinical practice, however, PCI has not yet widely accepted in Japan.

912

POSTER

Linac based helical intensity modulated total body irradiation

I.A. Popescu¹, C. Duzenli¹, M.J. Beasley², K. Goddard², T. Teke, Y. Qiu, S.D. Thomas, C. Yuen, K. Otto¹. ¹BC Cancer Agency, Medical Physics, Vancouver, BC, Canada; ²BC Cancer Agency, Radiation Oncology, Vancouver, BC, Canada

Background: Total body irradiation (TBI) is frequently used in a conditioning regimen for patients undergoing bone marrow transplantation. While achieving a high level of success, TBI does carry with it significant risk for early and late toxicity, particularly for lung. The ability to selectively lower radiation dose to the lungs may reduce the incidence of symptomatic and life-threatening pneumonitis and allow TBI to be used in cases where compromised lung function would have previously precluded this. We present a new linac based treatment modality for TBI, which allows us to limit dose to organs at risk such as lungs and kidneys, without compromising dose to the rest of the body.

Materials and Methods: Our technique makes use of a helical beam delivery path defined by simultaneous gantry rotation and couch translation. MLC leaf positions and dose-rate are derived using a novel aperture based optimization method. Potential advantages of this technique are (1) critical structures may be spared without compromising target coverage, (2) a conventional isocentric 6MV linac and standard treatment couch is used, (3) on-board kV imaging may be used to monitor patient position on a daily basis, (4) helical beam delivery eliminates the need to turn the patient from prone to supine as is currently required in some standard TBI delivery methods.

Results: We will present treatment planning results obtained for our Varian Clinac iX linac. The first objective is to reproduce the dose distribution achievable in our current TBI technique (uniform dose ±10% to the entire body using a Cobalt-60 sweeping beam). Next we develop optimization strategies that allow conformal avoidance of critical normal structures (rather than defining a limited target such as total marrow or lymphatic system, which may risk higher relapse rates).